

# SPEAKERS IN LIFE SCIENCE LIVE 2019



**DIPAK KALRA**  
**President of the European Institute for Innovation through Health Data**

**Dipak Kalra**, PhD, FRCGP, FBCS, British, is President of The European Institute for Innovation through Health Data (i~HD). He plays a leading international role in research and development of Electronic Health Records, including the requirements and models to ensure the robust long-term preservation of clinical meaning and protection of privacy. He leads the development of ISO standards on EHR interoperability, personal health records, EHR requirements, and has contributed to several EHR security and confidentiality standards. Dipak has led multiple European projects in these areas, including Horizon 2020 and the IMI programme alongside pharma companies, hospitals and ICT companies. He recently co-led a €16m project on the re-use of EHR information for clinical research, EHR4CR, alongside ten global pharma. He is a partner in another IMI project, EMIF, on the development of a European clinical research platform federating multiple population health and cohort studies. Dipak also led an EU Network of Excellence on semantic interoperability, and is a partner in other EU projects on the sustainability of interoperability assets, the transatlantic sharing of patient summaries and quality labelling. Dipak is Professor of Health Informatics at University College London and Visiting Professor of Health Informatics at the University of Gent.



**LAURA ELO**  
**Research Director in Bioinformatics and Group Leader in Computational Biomedicine at Turku Centre for Biotechnology**

**Laura Elo**, PhD, is Research Director in Bioinformatics and Group Leader in Computational Biomedicine at Turku Centre for Biotechnology (University of Turku and Åbo Akademi University). Her multidisciplinary research group of more than 30 specialists develops computational tools and mathematical modelling methods for analyzing and interpreting data generated by modern high-throughput biotechnologies in a number of national and international research projects (e.g. Horizon 2020 and European Research Council ERC). The ultimate goal is to improve the diagnosis and treatment of complex diseases, such as diabetes and cancer.



**OLLI RAITAKARI**  
**Professor in Cardiovascular Medicine, Director of the Turku University Research Centre**

Professor **Olli Raitakari** is currently the Professor in Cardiovascular Medicine, Director of the Turku University Research Centre of Applied and Preventive Cardiovascular Medicine. He is coordinating two large Finnish studies into cardiovascular risk. In addition, he is currently the Principal Investigator of the STRIP Study housed at the University of Turku. Professor Raitakari has introduced the vascular epidemiology, the genetic epidemiology and the population metabolomics approaches in these studies. His work has allowed the development, modification and validation of the techniques involved in the measurement of subclinical atherosclerotic changes in the vasculature. The techniques have included work on heart and arterial structure/function using a variety of non-invasive imaging methods. The research has contributed to the understanding of pre-clinical development of atherosclerosis in children and young adults, including the effects of diet, life-style, psychological traits, metabolic risk factors, inflammation, hormones and genetic markers.



**Dr. GABBOUJ**  
**Professor of Signal Processing at the Department of Signal Processing, Tampere University of Technology**

**Dr. Gabbouj** is a Professor of Signal Processing at the Department of Signal Processing, Tampere University of Technology, Tampere, Finland, where he leads the Multimedia Research Group. Dr. Gabbouj is a Fellow of the IEEE, a member of the European Academy and the Finnish Academy of Science and Letters.



**LEE TIEN**  
**Technology & Innovation, Manager**



**ANDREW FRIED**  
**IBM Global Life Sciences Industry Leader**

**Andrew Fried** is IBM Global Life Sciences Industry Leader. Andrew helps clients address industry imperatives and save lives through the power of cognitive insights. He works with clients to advance the next generation of discovery and development, acting on insights to drive value, enhance relationships across the ecosystem and empowering people to make better decisions.

Andrew was IBM's Life Sciences Industry Leader for Europe between 2015-2108. Prior to transferring to Europe in July 2015, Andrew was IBM Life Sciences Industry Leader for China for 5 years. While in China Andrew worked with many leading multi-national companies and several Chinese Life Sciences companies who were leaders in their respective segment.

Before joining IBM in 2000, Andrew had a successful 14-year career with a leading strategy consulting company. He graduated from Melbourne University with a Bachelor of Arts, and Monash University (Melbourne, Australia) with a Bachelor of Business. Andrew has a Master of Business Administration from the International University of Japan and is a Fellow of the Financial Services Institute of Australasia. He was a three-term board member on a government enterprise with assets of over \$350M. He was a founding director of a successful dot.com start-up in the early 2000s.



**MARTIN COWIE**  
**Professor of Cardiology and Chair of Cardiology at Imperial College London**

Professor **Martin R Cowie**, MD, MSc, FRCP, FRC (Ed), FESC, FACC is Professor of Cardiology and Chair of Cardiology (Health Services Research) at the National Heart and Lung Institute at Imperial College London. He is an Honorary Consultant Cardiologist at the Royal Brompton and Harefield NHS Foundation Trust, and a Non-Executive Director of the National Institute for Health and Care Excellence (NICE). Professor Cowie gained his medical degree from the University of Aberdeen, UK, before undertaking an MSc in Epidemiology from the London School of Hygiene and Tropical Medicine, and completing his cardiology training. Professor Cowie's research interests focus on health technology assessment and delivery of efficient and effective care for patients with heart failure, with a particular focus on diagnostics, drugs, or devices. Professor Cowie is a founding member and past-Chairman of the British Society for Heart Failure, in addition to being a Fellow of the American College of Cardiology, and the European Society of Cardiology (ESC). He chairs the Digital Health Committee of the ESC. Professor Cowie was shortlisted for the NHS Digital Champion (Leadership) Award in 2017. Professor Cowie is an Associate Editor of Heart and Journal of the American College of Cardiology- Heart Failure, and is an editorial board member of several other journals. He has contributed chapters to many books, and has written a book for patients entitled "Living with Heart Failure A Guide for Patients". He has published 300 Pub-Med listed papers, and has a current h-index of 66.



**KRISTOFFER MIVING**  
**Digital Lead, Nordics & Baltics, Janssen**

Kristoffer Miving is Nordic and Baltic Digital Lead for Janssen, Pharmaceutical Companies of Johnson and Johnson.

His background comes from IT where he for over 20 years has enabled business value through the capabilities of IT, such as leading the global Janssen pilot for Salesforce.com and set the new EMEA standard for enabling clinical trial inclusions through social media.

His career spans over several global, regional and local position in a variety of roles and countries.

Kristoffer's current objective is through the digital team of seven, lead and evolve Janssen in the Digital era, developing innovative capabilities to succeed in a VUCA (Volatile, Uncertain, Complex, Ambiguous) world in accordance with the evolving expectations of our customers.



## **FRANK STAELENS**

**Director of Quality and Process Management, OLV Hospital Aalst-Asse-Ninove, Belgium**

**Frank Staelens** is Director of Quality and Process Management at the OLV Hospital Aalst-Asse-Ninove (Belgium). He has a background in both nursing and clinical research in the field of cardiology and has extensive experience in hospital management. He has a Master's degree in Social Health Sciences (Medical-Social Science) and a postgraduate in Patient Safety. He holds a chair in the board of several healthcare related institutions, i.e. King Baudouin Foundation and OLV Robotic Surgery Institute (ORSI). More recently, he has built and shared his vision on using medical and hospital data to measure and improve quality of care in hospitals. Safeguarding quality of care and patient safety is his area of expertise.



## **Prof. JASON SWEDLOW**

**University of Dundee**

**Jason Swedlow** earned a BA in Chemistry from Brandeis University in 1982 and PhD in Biophysics from UCSF in 1994. After a postdoctoral fellowship with Dr T. J. Mitchison at UCSF and then Harvard Medical School, Dr Swedlow established his own laboratory in 1998 at the Wellcome Trust Biocentre, University of Dundee, as a Wellcome Trust Career Development Fellow. He was awarded a Wellcome Trust Senior Research Fellowship in 2002 and named Professor of Quantitative Cell Biology in 2007. His lab focuses on studies of mitotic chromosome structure and dynamics and has published numerous leading papers in the field. He is co-founder of the Open Microscopy Environment (OME), a community-led open source software project that develops specifications and tools for biological imaging. In 2005, he founded Glencoe Software, Inc., a commercial start-up that provides commercial licenses and customization for OME software. In 2011, Prof Swedlow and the OME Consortium were named BBSRC's Social Innovator of the Year and Overall Innovator of the Year. In 2012, he was named Fellow of the Royal Society of Edinburgh. Prof Swedlow has organized or directed several courses in quantitative microscopy at the Marine Biological Laboratory, Woods Hole, USA, Cold Spring Harbor Laboratory, USA and the National Centre for Biological Science, Bangalore, India.



## **Prof. JUUSO BLOMSTER**

**Chief Physician, Turku University Hospital**

**Juuso Blomster**, MD., PhD is associate professor in cardiology and currently holds the position of chief physician, Medical assessments and Innovations, South-West Finland Hospital District. Dr. Blomster has several years of experience in pharmaceutical research and outcome studies. Dr. Blomster has been involved in EHR4CR network since 2014 and his research is focused on digital development in clinical and cardiovascular medicine.



## **NIGEL HUGHES**

**Scientific Director of Real World Evidence, Janssen**

Scientific Director, Janssen Clinical Innovation Patient Data for Research (JCI-PDR), Janssen Pharm R&D. A former UK NHS healthcare & voluntary sector professional working in the pharmaceutical and diagnostics industry with a 360° experience in the blood borne virus market based on a professional heritage in the viral hepatitis, liver disease & HIV fields spanning thirty years, inclusive of ten years in the voluntary sector and being a Dept. of Health advisor. Formerly working for Roche, Gilead, Novartis, and now Janssen, he has focused latterly on strategic marketing for new diagnostic solutions for personalized medicine via bio-informatic tools, health information technologies and biomarkers in infectious or chronic diseases, with a particular emphasis on real world data. He worked on the IMI1 European Medical Information Framework (EMIF), and will be the Project Leader and co-lead for the (IMI2) European Health Data Network project, as well as working on integration of real world evidence into Janssen programmes, around the creation of digital cohorts. Married with two adult siblings, he lives in Belgium, in the countryside with his wife and ten cats.



## **TOMMI LEHTONEN**

**CEO co-founder at Blueprint Genetics**

**Tommi** is the CEO and co-founder of Blueprint Genetics, a clinical genetics company based in Helsinki, San Francisco, and Dubai. He has grown Blueprint into a team of 150 professionals and in his role splits his time between the Bay Area and Helsinki. Prior to Blueprint Genetics, Tommi founded a data analytics company called Whitevector and grew it to the Nordics and UK. Tommi holds a M.Sc. (Tech) from the Helsinki University of Technology where he studied business strategy and applied mathematics.



**TEEMU SUNA**  
**CEO and one of the founders of Nightingale Health Ltd**

**Teemu Suna** is the CEO and one of the founders of Nightingale Health Ltd, a Finnish biotech company reinventing global healthcare for chronic diseases. Standing at the helm of a major success story in the Finnish startup community, Suna has transformed Nightingale into an established growth company with over 60 employees in less than four years. Suna has over 15 years of experience in engineering and management positions, having previously served as Chief Technology Officer at Fujitsu Finland. As a passionate advocate for visionary healthcare solutions, Suna leads Nightingale on its mission to solve the global burden of chronic diseases, empowering people to follow-up on their own health and take actions to stay healthy. Under Suna's leadership, Nightingale has raised more than 20M€ in funding since Sept 2015.



**Dr NATHAN LEA**  
**Senior Research Associate at the UCL Institute of Health Informatics,  
London, UK**

**Nathan** is a Senior Research Associate at the UCL Institute of Health Informatics (IHI) working on projects in clinical care and research. His research interests include the role of information systems in supporting healthcare delivery and empowering patients, and Information Governance in the use of genetic, health and social care records in clinical research, particularly in the Age of Information and Big Data. Nathan has completed a PhD, which evaluated the effects of using knowledge management to represent policy based controls on participants' behaviour when handling healthcare information for clinical research. Outputs included the invention of the knowledge model called the Secutype and a policy tool to guide researchers on how to handle healthcare records in accordance with security policies. Nathan works on the Information Law and Governance In Clinical Practice and eHealth modules of the IHI's Health Informatics MSc and courses in UCL's MBBS. He has co-developed and deployed clinical information systems used at Whittington Health for Cardiovascular care and Dementia registries in partnership with the West London Mental Health Trust and UCL's Dementia Research Centre. Nathan works with the Farr Institute of Health Informatics Research and is a member of the Innovative Governance Group. He sits on the Athena SWAN Self Assessment Team and UCL's Security Working Group.



**BART VANNIEUWENHUYSE**  
**Senior Director Health Information Sciences, Janssen**

**Bart Vannieuwenhuyse** is Senior Director Health Information Sciences at Janssen, Pharmaceutical Companies of Johnson and Johnson. He joined Janssen Pharmaceutica as a clinical trial monitor in 1985. In the course of his career with Janssen, Bart has held a variety of marketing and sales positions, both at local operating company level (e.g. the Netherlands) and at international level. While in the Netherlands he was one of the pioneers that started "Healthy Solutions" a J&J daughter company that focused on developing integrated services in the healthcare field. Later, he was in the core team that developed the initial CRM approach for Janssen EMEA. Between 1999 and 2003, Bart spent 4 years in the IM department of Janssen Pharmaceutica in the US, where he was responsible for the e-business initiatives and for the overall IM technical architecture. Bart joined the EMEA CRM Center of Excellence in April 2003, where he prepared the CRM Roadmap for the short to mid-term. In 2009 Bart was instrumental in developing a new customer-orientation project for Janssen Europe. In 2011 Bart joined the Janssen R&D group to focus on external eHealth / Health Information projects with external partners. Currently, Bart is coordinator of the EMIF (European Medical Information Framework) project.



**PIETER VAN GALEN**  
**Patient representative**

**Pieter van Galen** is from the Netherlands and studied Business & Management in Alkmaar. During his studies he traveled extensively doing various internships (Hungary, Spain, England and China). After his studies he started a consultancy company dealing with training (communication and software) and change management. He has now been living in Belgium for nearly 20 years and enjoys the international environment of Brussels. He was finally diagnosed with MS in 2006, after many unrecognized symptoms for over 15 years. He is now actively involved as a patient advocate and is member of various steering groups related to MS and Big Data.



**Prof. PASCAL COOREVITS**  
**Professor, Ghent University, Vice President for Research, The EuroRec Institute, Ghent, Belgium**

**Pascal Coorevits** is Professor of Medical Informatics and Statistics at the Department of Public Health of the Faculty of Medicine and Health Sciences of the Ghent University (Belgium) and Vice President Research & Development of the European Institute for Health Records (EuroRec). He is also Director of RAMIT (Research in Advanced Medical Informatics and Telematics), an R&D spin-off platform of the Ghent University. He teaches several courses in biostatistics and eHealth related topics. His primary research interests lie in the domain of Electronic Health Records (EHRs) and are oriented towards various aspects of quality labelling and certification of EHRs (quality criteria, data quality characteristics, quality labelling and certification models, tools/methodologies for EHR evaluation and conformance testing, semantic interoperability aspects, secondary use of EHR data). Through EuroRec, RAMIT and the Ghent University he has participated in several EU -, national - and transatlantic eHealth research projects (e.g. ASSIST, EHR-Implement, EHR-Q TN, ARGOS, HITCH, Antilope, EHR4CR, SemanticHealthNet, EURECA, EXPAND,...).



**Dr CATHERINE CHRONAKI**  
**General Secretary, HL7 Foundation**

**Catherine Chronaki** is the General Secretary of the HL7 Foundation and is active in eHealth Policy and Standardization projects. Following the success of Trillium Bridge project on the transatlantic exchange of patient summaries, she leads the Trillium-II to scale up adoption of patient summaries in an innovative global community of practice. Catherine serves on the eHealth Stakeholders group of the European Commission and the board of the European Federation of Medical Informatics and she is member of the eHealth Unit of the European Society of Cardiology. Her talk will be on the recently released eStandards roadmap for a digital health compass to support trust and flow in cost-effective and sustainable large-scale eHealth deployment, building on actions of co-creation, governance, and alignment throughout the eStandards lifecycle.



**THOMAS ALLVIN**  
**Executive Director for Strategy and Healthcare Systems, EFPIA**

**Thomas Allvin** is Executive Director for Strategy and Healthcare Systems at the European Federation of Pharmaceutical Industries and Associations (EFPIA), where his responsibilities includes developing EFPIA's policies for data-driven, outcomes-based and sustainable healthcare systems. Before joining EFPIA in 2015, Thomas was Health Counsellor at the Permanent Representation of Sweden to the European Union, representing Sweden in the Council working parties for public health and pharmaceuticals & medical devices, and previously worked in several positions in the Swedish Ministry of Health and the Swedish Parliament.



**FILIP DE MEYER**  
**University Hospital of Ghent, Belgium**

Ing. **Filip De Meyer**, MSc. is a privacy expert of the medical informatics unit of the University Hospital of Ghent (Belgium). He is a former member of medical informatics security working groups (CEN-TC251, ISO-TC215 and co-author of ISO DTS 25237 on pseudonymisation). He has participated in several health informatics research projects, in which he focused on data-security and privacy enhancing technologies. He is involved in training programs of hospital information security officers and in privacy and security related courses of the university curriculum.



**SAARA MALKAMÄKI**  
**Specialist in Sitra, the Finnish Innovation Fund**

**Saara Malkamäki** works as a Specialist in Sitra, the Finnish Innovation Fund. Sitra is a future-oriented public think-and-do tank that promotes sustainable well-being and Finland's competitiveness. Saara builds fair data economy and engages people across Europe to create a method for data exchange and to set up European level rules and guidelines for ethical use of data. In parallel, and over the past few years Saara has been boosting health and social care innovations and setting up a one-stop shop for Finnish well-being data. Creating a better future is what Saara does and is passionate about. Follow Saara on Twitter @saara\_malkamaki



## **Dr NADIR AMMOUR**

### **Innovation and Partnership Patients & Sites, Transformation and Performance Office, Clinical Science & Operations, Sanofi R&D**

**Dr. Nadir Ammour** began his career as an oral surgeon in public healthcare moving into clinical development.

He is working to bring eHealth/Digital innovation in clinical development to deliver new medicines to patients faster.

He led several projects in that space such as the Verkko remote trial, Connected Hospitals Network (EHRs); wearables trials, and on-line patient recruitment.

Nadir is a member of the Executive Committee of the EHR4CR/InSite champion project. He is presently leading an EIT Health consortium project, EHR2EDC aiming at further developing capabilities to conduct trials using EHRs data to automatically prefill an eCRF.

Dr. Ammour held various global positions previously at Wyeth, now at Sanofi. He is graduated in medical informatics, health economics and an MBA from Reims Management School, besides his Doctorate in Medical Dentistry.



## **OLIVER ZOBELL**

### **Scientific Project Manager, Jülich**

After his formative years in academic research, in the field of genetic engineering, **Oliver** worked at the European Commission's Joint Research Centre (JRC), supporting EU-politics in the field of bioanalytics standardisation. Since 2015 he is working in the Life Sciences and Health Research Division of the Project Management Jülich, a leading regional, national and international research funding agency within the Research Centre Jülich in Germany. As Scientific Project Manager, he supports the German Ministry for Research and Education (BMBF) in developing and implementing its strategic research agenda in the field of Life Sciences and Health Research, including through transnational research collaborations. Since the start of 2019, Oliver is partaking in the EU-project DigitalHealthEurope (DHE), which supports the European Commission in realising the Digital Transformation of Health and Care in the Digital Single Market. His particular focus in the project is on the secondary use of health data for research.



## **JARI FORSSTRÖM**

### **Turku University Hospital and Abomics Ltd**

MD. **Jari Forsström** is a specialized internist and a startup entrepreneur. Mr. Forsström has been intensively involved in pharmacological related issues and developing the methods of utilizing safe and effective pharmacological treatment in Scandinavia.

“Medicine is in the core of every physician's work. Having the knowledge of how to treat patients individually is these days possible due to pharmacogenetic. Personalized medicine is here to stay.”

At the moment Mr. Forsström is one of the leading experts in the field of pharmacogenetic. Based on intensive academic research, it is repeatedly shown that with pharmacogenetic it is possible to reduce the risk of consuming unsuitable medication, minimize the unpleasant side-effects and to ensure effective medical treatment. This is not only humane, but also very cost-effective way to implement personalized medicine..



## **ANTTI KANGAS**

### **CTO & Co-Founder, Nightingale Health Ltd.**

Personalised healthcare is being described mostly in very technical terms, with the end goal of establishing a stack of technologies. Articles, books and blog posts are filled with words like biobanks, big data, AI, computing, 'omics, wearables and monitoring. While we're probably going to need these, and many more technologies to implement personalised healthcare, technology should not be the goal in and of itself. In my talk, I will demonstrate a value-based and human-centric approach to define personalised healthcare and show, how we can use technology to achieve that.



## **ANTTI KARLSSON**

### **Development Manager, Auria Biobank**



**ION PETRE**  
**Professor, University of Turku**

Network Controllability: Algorithmics for precision cancer medicine

Cancer is a systemic disease that involves accumulated changes on many different levels. It is also a highly heterogenous disease: from patient to patient it manifests in different ways and so the best way to fight the disease may be different from patient to patient, hence the need to personalize medical approaches. Most current cancer treatments come with serious side effects: they affect indiscriminately both cancer cells and healthy cells, hence the need for targeted/precision. On the other hand we have been very successful at collecting detailed data about patients in many parts of the world: molecular, genetic, clinical data. I will discuss an approach where data on a patient's mutations and unusually expressed genes is integrated with data from other patients and literature studies to identify new disease mechanisms and new therapeutical approaches. The framework we work on is network controllability. I discuss our recent results on breast-, pancreatic, and ovarian- cancer and the perspectives of this line of work for patient-specific therapeutic predictions.



**PETRI VIROLAINEN**  
**Hospital Director of Turku University Hospital. Chief Medical Officer**

Surgeon, Orthopedic Doctor, subspecialized in hip and knee total joint primary and revision arthroplasty. Special scientific interest on adult reconstructive surgery.

Active member in various national and international orthopedic societies and expert groups.

Past President of Finnish Orthopedic Association and Finnish Arthroplasty Society.

Past member of Board of the Finnish Surgical Society, Nordic Orthopedic Federation

Finnish Delegate of EFORT and UEMS (ortho section), member of various adviser boards.

Special interest on data lakes and disease-specific registries that enables cost-effectiveness and value based medicine.